PT883406E - Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente - Google Patents

Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente

Info

Publication number
PT883406E
PT883406E PT97907134T PT97907134T PT883406E PT 883406 E PT883406 E PT 883406E PT 97907134 T PT97907134 T PT 97907134T PT 97907134 T PT97907134 T PT 97907134T PT 883406 E PT883406 E PT 883406E
Authority
PT
Portugal
Prior art keywords
auto
insulinodependente
treatment
diabetes mellitus
immune diseases
Prior art date
Application number
PT97907134T
Other languages
English (en)
Inventor
Jean-Francois Bach
Jean-Marc Gombert
Andre Herbelin
Michel Morre
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PT883406E publication Critical patent/PT883406E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PT97907134T 1996-02-28 1997-02-26 Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente PT883406E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9602501A FR2745185B1 (fr) 1996-02-28 1996-02-28 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Publications (1)

Publication Number Publication Date
PT883406E true PT883406E (pt) 2004-08-31

Family

ID=9489676

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97907134T PT883406E (pt) 1996-02-28 1997-02-26 Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente

Country Status (13)

Country Link
US (2) US6713053B1 (pt)
EP (1) EP0883406B1 (pt)
JP (1) JP3138481B2 (pt)
AT (1) ATE264112T1 (pt)
AU (1) AU1929397A (pt)
BR (1) BR9707776A (pt)
DE (1) DE69728654T2 (pt)
DK (1) DK0883406T3 (pt)
ES (1) ES2217396T3 (pt)
FR (1) FR2745185B1 (pt)
NO (1) NO321569B1 (pt)
PT (1) PT883406E (pt)
WO (1) WO1997031648A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2791322A1 (en) 2011-12-12 2014-10-22 Cell Medica Limited Process of expanding t cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US20150010519A1 (en) 2012-02-09 2015-01-08 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CA2923314A1 (en) 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute Modulation of .gamma..delta.t cells
WO2017049291A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Also Published As

Publication number Publication date
NO983917L (no) 1998-10-28
ES2217396T3 (es) 2004-11-01
WO1997031648A1 (fr) 1997-09-04
US6713053B1 (en) 2004-03-30
JP3138481B2 (ja) 2001-02-26
DE69728654D1 (de) 2004-05-19
BR9707776A (pt) 1999-07-27
FR2745185B1 (fr) 1998-05-15
EP0883406B1 (fr) 2004-04-14
NO983917D0 (no) 1998-08-26
FR2745185A1 (fr) 1997-08-29
US20040180037A1 (en) 2004-09-16
NO321569B1 (no) 2006-06-06
ATE264112T1 (de) 2004-04-15
EP0883406A1 (fr) 1998-12-16
DK0883406T3 (da) 2004-08-02
AU1929397A (en) 1997-09-16
JPH11508605A (ja) 1999-07-27
DE69728654T2 (de) 2005-03-24

Similar Documents

Publication Publication Date Title
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
NO890587L (no) Nye proteiner med faktor viii aktivitet: fremgangsmaate for fremstilling derav ved anvendelse av genetisk omkonstruerte celler og farmasoeytiske sammensetninger som inneholderdisse.
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
NO933171L (no) Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer
DE69233029D1 (de) Menschliche mesenchym-stammzellen aus dem mark und monoklonale antikörper spezifisch gegen diese zellen
DE69531098D1 (de) Piperidine und pyrrolidine
KR900700073A (ko) 결합 유도 조성물
DE3879873D1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3763851D1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
DE3682811D1 (de) Pharmazeutische zusammensetzung zur heilung und verhuetung kardiovaskularer krankheiten und verfahren zu ihrer herstellung.
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
WO2004043990A3 (en) Human stem cell materials and methods
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
DE69520430D1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
DE69133077T2 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
ATE409042T1 (de) Verwendung von sulodexide zur behandlung von diabetischer nephropathie
TR199901385T2 (xx) Piperidin t�revleri.
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.